Which has stronger earnings and valuation, RADX or IMUX?

Radiopharm Theranostics has higher revenue and earnings than Immunic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is RADX or IMUX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Immunic N/A -220.75% -132.04%

Which has higher valuation and earnings, ABOS or RADX?

Radiopharm Theranostics has higher revenue and earnings than Acumen Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Is ABOS or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Radiopharm Theranostics N/A N/A N/A

Does the media refer more to ABOS or RADX?

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Radiopharm Theranostics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, CRBU or RADX?

Radiopharm Theranostics has lower revenue, but higher earnings than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caribou Biosciences $11.16M 14.66 -$148.12M -$1.42 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Which has stronger earnings & valuation, RADX or EQ?

Equillium has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A Equillium $41.10M 4.05 -$22.40M -$0.32 N/A

Is RADX or EQ more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Equillium N/A -61.43% -53.72%

Does the media refer more to RADX or EQ?

In the previous week, Equillium had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Equillium and 1 mentions for Radiopharm Theranostics. Equillium's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ACOG or RADX?

Alpha Cognition has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.22M 16.81 -$20.67M -$1.35 N/A Radiopharm Theranostics $2.35M 21.56 -$24.83M N/A N/A

Does the media prefer ACOG or RADX?

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Radiopharm Theranostics (RADX) Competitors

$4.29 +0.01 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 +0.09 (+1.98%)

As of 07:55 PM Eastern

Compare

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

Should you buy Radiopharm Theranostics stock or one of its competitors? MarketBeat compares Radiopharm Theranostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Radiopharm Theranostics include Immunic (IMUX), Acumen Pharmaceuticals (ABOS), Caribou Biosciences (CRBU), Equillium (EQ), and Alpha Cognition (ACOG). These companies are all part of the "med - biomed/gene" industry.

How does Radiopharm Theranostics compare to Immunic?

Radiopharm Theranostics (NASDAQ:RADX) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Radiopharm Theranostics currently has a consensus target price of $11.00, indicating a potential upside of 156.41%. Immunic has a consensus target price of $47.57, indicating a potential upside of 214.00%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Radiopharm Theranostics has higher revenue and earnings than Immunic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Radiopharm Theranostics has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Immunic	N/A	-220.75%	-132.04%

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for Immunic. Radiopharm Theranostics' average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Immunic	Neutral

Summary

Radiopharm Theranostics and Immunic tied by winning 6 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Radiopharm Theranostics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Radiopharm Theranostics	N/A	N/A	N/A

Radiopharm Theranostics has higher revenue and earnings than Acumen Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Acumen Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 258.74%. Radiopharm Theranostics has a consensus price target of $11.00, suggesting a potential upside of 156.41%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Radiopharm Theranostics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Summary

Acumen Pharmaceuticals and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Radiopharm Theranostics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Radiopharm Theranostics' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Radiopharm Theranostics	N/A	N/A	N/A

Caribou Biosciences has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Caribou Biosciences presently has a consensus target price of $8.67, indicating a potential upside of 425.25%. Radiopharm Theranostics has a consensus target price of $11.00, indicating a potential upside of 156.41%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics has lower revenue, but higher earnings than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	14.66	-$148.12M	-$1.42	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Overall Sentiment
Caribou Biosciences	Neutral
Radiopharm Theranostics	Neutral

Summary

Caribou Biosciences beats Radiopharm Theranostics on 7 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Equillium?

Radiopharm Theranostics (NASDAQ:RADX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

Radiopharm Theranostics presently has a consensus price target of $11.00, indicating a potential upside of 156.41%. Equillium has a consensus price target of $7.57, indicating a potential upside of 187.89%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Equillium has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A
Equillium	$41.10M	4.05	-$22.40M	-$0.32	N/A

In the previous week, Equillium had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Equillium and 1 mentions for Radiopharm Theranostics. Equillium's average media sentiment score of 0.25 beat Radiopharm Theranostics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Radiopharm Theranostics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Equillium beats Radiopharm Theranostics on 11 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Alpha Cognition has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	16.81	-$20.67M	-$1.35	N/A
Radiopharm Theranostics	$2.35M	21.56	-$24.83M	N/A	N/A

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Alpha Cognition presently has a consensus price target of $16.00, indicating a potential upside of 102.79%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 156.41%. Given Radiopharm Theranostics' higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Radiopharm Theranostics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Alpha Cognition and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.56M	$3.64B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.79	27.00	24.19
Price / Sales	21.56	317.81	517.32	92.93
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.22	8.17	10.67	6.26
Net Income	-$24.83M	$23.81M	$3.60B	$331.76M
7 Day Performance	-0.23%	-1.16%	-0.37%	-1.10%
1 Month Performance	-3.60%	2.59%	1.80%	-1.29%
1 Year Performance	-0.46%	45.43%	25.50%	18.84%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	2.6055 of 5 stars	$4.29 +0.2%	$11.00 +156.4%	-3.4%	$50.56M	$2.35M	N/A	N/A	Positive News
IMUX Immunic	2.6702 of 5 stars	$14.77 -0.1%	$47.57 +222.1%	+55.6%	$201.33M	N/A	N/A	70
ABOS Acumen Pharmaceuticals	2.4545 of 5 stars	$2.63 -2.6%	$8.00 +204.2%	+47.3%	$195.01M	N/A	N/A	20
CRBU Caribou Biosciences	1.7338 of 5 stars	$1.93 -0.8%	$8.67 +350.2%	-21.0%	$192.41M	$11.16M	N/A	100
EQ Equillium	2.7386 of 5 stars	$2.91 -1.7%	$7.57 +160.2%	+495.0%	$187.15M	$41.10M	N/A	40	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

How does Radiopharm Theranostics compare to Immunic?

Summary

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Summary

How does Radiopharm Theranostics compare to Equillium?

Summary

How does Radiopharm Theranostics compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. IMUX, ABOS, CRBU, EQ, and ACOG

How does Radiopharm Theranostics compare to Immunic?

Do institutionals and insiders believe in RADX or IMUX?

Do analysts recommend RADX or IMUX?

Which has stronger earnings and valuation, RADX or IMUX?

Which has more risk and volatility, RADX or IMUX?

Is RADX or IMUX more profitable?

Does the media favor RADX or IMUX?

Summary

How does Radiopharm Theranostics compare to Acumen Pharmaceuticals?

Is ABOS or RADX more profitable?

Which has higher valuation and earnings, ABOS or RADX?

Do insiders & institutionals hold more shares of ABOS or RADX?

Do analysts rate ABOS or RADX?

Does the media refer more to ABOS or RADX?

Which has more volatility and risk, ABOS or RADX?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Is CRBU or RADX more profitable?

Which has more risk & volatility, CRBU or RADX?

Do institutionals and insiders believe in CRBU or RADX?

Do analysts rate CRBU or RADX?

Which has higher earnings and valuation, CRBU or RADX?

Does the media favor CRBU or RADX?

Summary

How does Radiopharm Theranostics compare to Equillium?

Is RADX or EQ more profitable?

Do analysts prefer RADX or EQ?

Do insiders and institutionals have more ownership in RADX or EQ?

Which has stronger earnings & valuation, RADX or EQ?

Does the media refer more to RADX or EQ?

Which has more risk and volatility, RADX or EQ?

Summary

How does Radiopharm Theranostics compare to Alpha Cognition?

Which has higher valuation & earnings, ACOG or RADX?

Does the media prefer ACOG or RADX?

Which has more volatility & risk, ACOG or RADX?

Do analysts rate ACOG or RADX?

Is ACOG or RADX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools